Merck Serono announced that a global pharma licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene for $232 million.
This pharma licensing deal is for the compound BeiGene-290, which is a potent poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of cancer.
It is currently in preclinical development and is expected to enter clinical development next year.
BeiGene will be responsible for the development and commercialization of BeiGene-290 in China.
Merck will be responsible for the development and commercialization of BeiGene-290 for the rest of the world.
BeiGene will receive an undisclosed upfront payment.
It is eligible to receive further payments of up to EUR 170 million (US$ 232 million) for the achievement of clinical development and potential commercial milestones in both the People's Republic of China and rest of the world, as well as royalties on net sales.
Read the full press release at PR Newswire
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Merck KgaA / Merck Serono
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity